Methylated eicosapentaenoic acid and tetradecylthioacetic acid: effects on fatty acid metabolism.
We introduced methyl or ethyl groups to the 2- or 3-position of the eicosapentaenoic acid (EPA) molecule to investigate whether the branching of EPA could influence its hypolipidemic effect in rats. The most effective branching involved two methyl groups in the 2-position and one methyl group in the 3-position. These EPA derivatives increased hepatic mitochondrial and peroxisomal beta-oxidation and decreased plasma lipids concomitant with suppressed acetyl-coenzyme A (CoA) carboxylase (EC 6.4.1.2) and fatty acid synthase (EC 2.3.1.85) activities. This was followed by elevated activities of camitine O-palmitoyltransferase (EC 2.3.1.21) and possibly 2,4-dienoyl-CoA reductase (EC 1.3.1.34), as well as induced mRNA levels of these enzymes and fatty acyl-CoA oxidase. The fatty acid composition in liver changed, with an increased 18:1 n-9 content, whereas the expression of delta9-desaturase remained unchanged. We investigated the flux of fatty acids in cultured hepatocytes, and found that oxidation of [1-14C]-labeled palmitic acid increased but the secretion of palmitic acid-labeled triglycerides decreased after addition of 2-methyl-EPA. The fatty acyl-CoA oxidase (EC 1.3.3.6) activity in these cells remained unchanged. A significant negative correlation was obtained between palmitic acid oxidation and palmitic acid-labeled synthesized triglycerides. To investigate whether the hypolipidemic effect occurred independently of induced peroxisomal beta-oxidation, we fed rats 2-methyl-tetradecylthioacetic acid. This compound increased the peroxisomal but not the mitochondrial beta-oxidation, and the plasma lipid levels were unchanged. In conclusion, EPA methylated in the 2- or 3-position renders it more potent as a hypolipidemic agent. Furthermore, this study supports the hypothesis that the mitochondrion is the primary site for the hypolipidemic effect.
Vaagenes
H
H
Department of Clinical Biochemistry, University of Bergen, Haukeland Hospital, Norway. Hege.Vagenes@ikb.uib.no
Madsen
L
L
Dyrøy
E
E
Elholm
M
M
Stray-Pedersen
A
A
Frøyland
L
L
Lie
O
O
Berge
R K
RK
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D002478:Cells, Cultured; D015118:Eicosapentaenoic Acid / Q000378:metabolism / Q000494:pharmacology*; D005227:Fatty Acids / Q000378:metabolism*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000166:cytology / Q000187:drug effects; D008297:Male; D008745:Methylation; D008830:Microbodies / Q000187:drug effects* / Q000201:enzymology; D008930:Mitochondria, Liver / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D010084:Oxidation-Reduction; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013440:Sulfides / Q000378:metabolism / Q000494:pharmacology*
D000975:Antioxidants; D005227:Fatty Acids; D008055:Lipids; D012333:RNA, Messenger; D013440:Sulfides; C062078:1-(carboxymethylthio)tetradecane; D015118:Eicosapentaenoic Acid